TCM
LXRX icon

Traynor Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Traynor Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,909
Closed -$23.9K – 259
2023
Q3 		$23.9K Buy
21,909
+1,103
+5% +$1.94K ﹤0.01% 213
2023
Q2 		$47.6K Buy
20,806
+1,742
+9% +$4.62K 0.01% 202
2023
Q1 		$46.3K Buy
+19,064
New +$43.7K 0.01% 197

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Traynor Capital Management's LXRX Position: Q4 2023 in Review

Traynor Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 21,909 shares — an estimated $23.9K sold.

Traynor Capital Management first reported a position in LXRX in Q1 2023 and held it in 3 quarters. The position peaked at $47.6K in Q2 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

  • Traynor Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Traynor Capital Management sold 21,909 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $23.9K.
  • Traynor Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Traynor Capital Management's Lexicon Pharmaceuticals position peaked at $47.6K in Q2 2023.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Traynor Capital Management's 13F filing for Q4 2023, filed 18 Jan 2024.